

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on our website at <http://www.sharedresearch.jp> and various professional platforms. Our sponsored research reports provide an in-depth and informative view of the companies we cover, and contain the latest available information updated in a timely manner.

On **September 21, 2017**, SymBio Pharmaceuticals Ltd. announced revisions to its full-year FY12/17 earnings forecasts.

Revised FY12/17 company earnings forecasts

- ▷ Sales: JPY3.6bn (previous forecast: JPY2.9bn)
- ▷ Operating loss: JPY3.9bn (JPY3.2bn)
- ▷ Recurring loss: JPY4.0bn (JPY3.3bn)
- ▷ Net loss: JPY4.0bn (JPY3.3bn)

Reasons for revisions

The company expects sales of JPY3.6bn, exceeding its previous forecast by JPY680mn, because sales of Treakisym® in Japan grew faster than expected following approval for the new indication of first-line treatment of low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL) in December 2016. The company expects operating profit, recurring profit, and net profit to be lower than its previous forecast due to the upfront payment relating to the license agreement with Eagle Pharmaceuticals, Inc., for the liquid formulation products of bendamustine hydrochloride, although SG&A expenses have been solidly controlled within budget.

This note is the most recent addition to the [full report](#).

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <http://www.sharedresearch.jp>.

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion by us that could influence investment decisions in the company, such opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.

Contact Details

Shared Research Inc.

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

<http://www.sharedresearch.jp>

Phone: +81 (0)3 5834-8787

Email: info@sharedresearch.jp